Ken Griffin Clearside Biomedical, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$0.93 - $1.35 $33,666 - $48,870	36,200 Added 36200.0%	36,300 $46,000
Q2 2024 Aug 14, 2024	SELL	$1.08 - $1.58 $108 - $158	-100 Reduced 50.0%	100 $0
Q1 2024 May 15, 2024	SELL	$1.2 - $2.02 $11,280 - $18,988	-9,400 Reduced 97.92%	200 $0
Q4 2023 Feb 14, 2024	SELL	$0.68 - $1.18 $1,428 - $2,478	-2,100 Reduced 17.95%	9,600 $11,000
Q3 2023 Nov 14, 2023	SELL	$0.82 - $1.27 $1,804 - $2,794	-2,200 Reduced 15.83%	11,700 $10,000
Q1 2023 May 15, 2023	SELL	$0.93 - $1.66 $3,441 - $6,142	-3,700 Reduced 21.02%	13,900 $14,000
Q4 2022 Feb 14, 2023	BUY	$1.0 - $1.5 $17,600 - $26,400	17,600 New	17,600 $19,000

12.2M

54.7K

50.7K

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $64.4M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.